| Journal of Hematology, ISSN 1927-1212 print, 1927-1220 online, Open Access |
| Article copyright, the authors; Journal compilation copyright, J Hematol and Elmer Press Inc |
| Journal website https://www.thejh.org |
Short Communication
Volume 12, Number 3, June 2023, pages 105-108
Real-World Data of Crizanlizumab in Sickle Cell Disease: A Single-Center Analysis
Table
| Subject ID | SCD genotype | Pre-crizanlizumab acute visits | Post-crizanlizumab acute visits | Doses received | Concomitant SCD medications | Reason for discontinuation of crizanlizumab |
|---|---|---|---|---|---|---|
| SCD: sickle cell disease. | ||||||
| 1 | Hb SS | 57 | 25 | 6 | L-glutamine | Unable to keep appointments |
| 2 | Hb S/β0 | 59 | 33 | 6 | None | Unable to keep appointments |
| 3 | Hb SS | 17 | 0 | 4 | Voxelotor | Transportation issues |
| 4 | Hb S/β0 | 27 | 7 | 4 | None | Unable to keep appointments |
| 5 | Hb SS | 9 | 9 | 7 | L-glutamine | Perceived lack of efficacy |
| 6 | Hb SS | 0 | 0 | 5 | Hydroxyurea | Unable to keep appointments |
| 7 | Hb SC | 0 | 0 | 7 | None | Continues on med |
| 8 | Hb SS | 0 | 4 | 9 | Voxelotor | More pain |
| 9 | Hb SS | 12 | 16 | 6 | Hydroxyurea | Unable to keep appointments |